Super CAR-T not checked

Guangzhou FineImmune Biotechnology Co., LTD.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1 trial completes
Trials
1 active
1 in total
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“All participators received lymphoid-depleted preconditioning before Super CAR-T cells infusion. Super CAR-T cells were infused 3 days later.”In the company’s words, NCT07493044 on ClinicalTrials.gov
Tested for
Advanced Hepatocellular Carcinoma (HCC), GPC3 Positive Hepatocellular Carcinoma
Main trialPhase 1
“This study was a phase I safety and tolerability clinical trial conducted in a single-center, open-label, 3+3 design with dose escalation.”In the company’s words, NCT07493044 on ClinicalTrials.gov

Other drugs for Advanced Hepatocellular Carcinoma (HCC)

All 130 drugs for Advanced Hepatocellular Carcinoma (HCC)

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Recruiting 30 Apr 2028 An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Super CAR-T

Following is part of Solo: you see every change to Super CAR-T the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in